First Time Loading...

Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 11.05 USD 5.24% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

PHAT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. [ Read More ]

The intrinsic value of one PHAT stock under the Base Case scenario is 12.05 USD. Compared to the current market price of 11.05 USD, Phathom Pharmaceuticals Inc is Undervalued by 8%.

Key Points:
PHAT Intrinsic Value
Base Case
12.05 USD
Undervaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Phathom Pharmaceuticals Inc

Backtest PHAT Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PHAT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Phathom Pharmaceuticals Inc's business.

What risks and challenges
does Phathom Pharmaceuticals Inc face in the near future?

Summarize the latest earnings report
of Phathom Pharmaceuticals Inc.

Provide P/E
for Phathom Pharmaceuticals Inc and its competitors.

Financials

Balance Sheet Decomposition
Phathom Pharmaceuticals Inc

Current Assets 397.4m
Cash & Short-Term Investments 381.4m
Receivables 1.6m
Other Current Assets 14.4m
Non-Current Assets 16.4m
PP&E 3.6m
Other Non-Current Assets 12.8m
Current Liabilities 38.8m
Accounts Payable 12.6m
Accrued Liabilities 19.1m
Other Current Liabilities 7.1m
Non-Current Liabilities 447.8m
Long-Term Debt 437.7m
Other Non-Current Liabilities 10.2m
Efficiency

Earnings Waterfall
Phathom Pharmaceuticals Inc

Revenue
682k USD
Cost of Revenue
-167k USD
Gross Profit
515k USD
Operating Expenses
-167.8m USD
Operating Income
-167.3m USD
Other Expenses
-34.3m USD
Net Income
-201.6m USD

Free Cash Flow Analysis
Phathom Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

PHAT Profitability Score
Profitability Due Diligence

Phathom Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Exceptional ROE
60/100
Profitability
Score

Phathom Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

PHAT Solvency Score
Solvency Due Diligence

Phathom Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
42/100
Solvency
Score

Phathom Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHAT Price Targets Summary
Phathom Pharmaceuticals Inc

Wall Street analysts forecast PHAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHAT is 23.17 USD with a low forecast of 10.1 USD and a high forecast of 29.4 USD.

Lowest
Price Target
10.1 USD
9% Downside
Average
Price Target
23.17 USD
110% Upside
Highest
Price Target
29.4 USD
166% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PHAT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PHAT Price
Phathom Pharmaceuticals Inc

1M 1M
+3%
6M 6M
+7%
1Y 1Y
+61%
3Y 3Y
-70%
5Y 5Y
-55%
10Y 10Y
-55%
Annual Price Range
11.05
52w Low
6.21
52w High
15.7
Price Metrics
Average Annual Return -11.55%
Standard Deviation of Annual Returns 33.59%
Max Drawdown -89%
Shares Statistics
Market Capitalization 566.7m USD
Shares Outstanding 51 289 100
Percentage of Shares Shorted 21.55%

PHAT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

566.7m USD

Dividend Yield

0%

Description

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Contact

NEW JERSEY
Florham Park
100 Campus Drive,, Suite 102
+18777428466.0
https://www.phathompharma.com/

IPO

2019-10-25

Employees

77

Officers

President, CEO & Director
Ms. Terrie J. Curran
Co-Founder & Director
Mr. David A. Socks
Co-Founder & COO
Dr. Azmi Nabulsi M.D., M.P.H.
Chief Financial & Business Officer
Ms. Molly Henderson CPA, MBA
Co-Founder
Dr. Aditya Kohli Ph.D.
General Counsel & Secretary
Mr. Lawrence Miller Esq., J.D.
Show More
Chief Development Sciences Officer
Mr. Tom Harris
Chief Medical Officer
Dr. Eckhard Leifke M.D., Ph.D.
Chief Commercial Officer
Mr. Martin J. Gilligan
Show Less

See Also

Discover More
What is the Intrinsic Value of one PHAT stock?

The intrinsic value of one PHAT stock under the Base Case scenario is 12.05 USD.

Is PHAT stock undervalued or overvalued?

Compared to the current market price of 11.05 USD, Phathom Pharmaceuticals Inc is Undervalued by 8%.